DjordjeAtanackovicMD

Hematology • Baltimore, MD

Associate Professor, Internal Medicine, University of Utah Sch of Med

Join to view full profile

Dr. Atanackovic is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Atanackovic's full profile

Already have an account?

Office
655 W. Baltimore Street
Baltimore, MD 21201
Phone+1 410-706-1946

Fax+1 410-328-6559

Education & Training

Freie University Berlin Faculty of MedicineClass of 1998

Certifications & Licensure

MD State Medical License 2020 - 2026
UT State Medical License 2013 - 2026

Publications & Presentations

PubMed

162 citations
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Saad Z. Usmani, Fredrik Schjesvold, Albert Oriol, Lionel Karlin, Michele Cavo
The Lancet. Haematology. 2019-09-01
173 citations
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Maria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, Albert Oriol, David Simpson
The Lancet. Haematology. 2019-07-18
22 citations
An Anti-Programmed Death-1 Antibody (αPD-1) Fusion Protein That Self-Assembles into a Multivalent and Functional αPD-1 Nanoparticle.
Peng Zhao, Djordje Atanackovic, Shuyun Dong, Hideo Yagita, Xiao He
Molecular Pharmaceutics. 2017-04-19

Abstracts/Posters

B Cell Maturation Antigen-Specific CAR T Cells for Relapsed or Refractory Multiple Myeloma: A Meta-Analysis
Djordje Atanackovic, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
B Cell Maturation Antigen-Specific CAR T Cells for Relapsed or Refractory Multiple Myeloma: A Meta-Analysis
Djordje Atanackovic, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

New Cancer Treatment Changing Outlook for Those with Blood CancersJuly 11th, 2022
COVID Vaccine Protection May Be Weaker in Some Cancer Patients. But Experts Say They Should Still Get VaccinatedMay 17th, 2021
Phase 1 Trial Featuring First shRNA-Edited CAR-T Therapy to BeginSeptember 9th, 2020
Join now to see all